Metabolic reprogramming in triple-negative breast cancer

Cancer Biol Med. 2020 Feb 15;17(1):44-59. doi: 10.20892/j.issn.2095-3941.2019.0210.

Abstract

Since triple-negative breast cancer (TNBC) was first defined over a decade ago, increasing studies have focused on its genetic and molecular characteristics. Patients diagnosed with TNBC, compared to those diagnosed with other breast cancer subtypes, have relatively poor outcomes due to high tumor aggressiveness and lack of targeted treatment. Metabolic reprogramming, an emerging hallmark of cancer, is hijacked by TNBC to fulfill bioenergetic and biosynthetic demands; maintain the redox balance; and further promote oncogenic signaling, cell proliferation, and metastasis. Understanding the mechanisms of metabolic remodeling may guide the design of metabolic strategies for the effective intervention of TNBC. Here, we review the metabolic reprogramming of glycolysis, oxidative phosphorylation, amino acid metabolism, lipid metabolism, and other branched pathways in TNBC and explore opportunities for new biomarkers, imaging modalities, and metabolically targeted therapies.

Keywords: Metabolic reprogramming; Warburg effect; aerobic glycolysis; cancer stem cell; targeted therapy; triple-negative breast cancer.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Amino Acids / metabolism
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Biomarkers, Tumor / analysis
  • Biomarkers, Tumor / metabolism
  • Female
  • Humans
  • Lipid Metabolism / drug effects*
  • Molecular Targeted Therapy / methods
  • Oxidative Phosphorylation / drug effects*
  • Triple Negative Breast Neoplasms / diagnosis
  • Triple Negative Breast Neoplasms / drug therapy
  • Triple Negative Breast Neoplasms / pathology*
  • Warburg Effect, Oncologic / drug effects*

Substances

  • Amino Acids
  • Antineoplastic Agents
  • Biomarkers, Tumor